Literature DB >> 29361245

Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.

Nicoletta Anzalone1, Antonella Castellano1, Marcello Cadioli1, Gian Marco Conte1, Valeria Cuccarini1, Alberto Bizzi1, Marco Grimaldi1, Antonella Costa1, Giovanni Grillea1, Paolo Vitali1, Domenico Aquino1, Maria Rosa Terreni1, Valter Torri1, Bradley J Erickson1, Massimo Caulo1.   

Abstract

Purpose To evaluate the feasibility of a standardized protocol for acquisition and analysis of dynamic contrast material-enhanced (DCE) and dynamic susceptibility contrast (DSC) magnetic resonance (MR) imaging in a multicenter clinical setting and to verify its accuracy in predicting glioma grade according to the new World Health Organization 2016 classification. Materials and Methods The local research ethics committees of all centers approved the study, and informed consent was obtained from patients. One hundred patients with glioma were prospectively examined at 3.0 T in seven centers that performed the same preoperative MR imaging protocol, including DCE and DSC sequences. Two independent readers identified the perfusion hotspots on maps of volume transfer constant (Ktrans), plasma (vp) and extravascular-extracellular space (ve) volumes, initial area under the concentration curve, and relative cerebral blood volume (rCBV). Differences in parameters between grades and molecular subtypes were assessed by using Kruskal-Wallis and Mann-Whitney U tests. Diagnostic accuracy was evaluated by using receiver operating characteristic curve analysis. Results The whole protocol was tolerated in all patients. Perfusion maps were successfully obtained in 94 patients. An excellent interreader reproducibility of DSC- and DCE-derived measures was found. Among DCE-derived parameters, vp and ve had the highest accuracy (are under the receiver operating characteristic curve [Az] = 0.847 and 0.853) for glioma grading. DSC-derived rCBV had the highest accuracy (Az = 0.894), but the difference was not statistically significant (P > .05). Among lower-grade gliomas, a moderate increase in both vp and rCBV was evident in isocitrate dehydrogenase wild-type tumors, although this was not significant (P > .05). Conclusion A standardized multicenter acquisition and analysis protocol of DCE and DSC MR imaging is feasible and highly reproducible. Both techniques showed a comparable, high diagnostic accuracy for grading gliomas. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29361245     DOI: 10.1148/radiol.2017170362

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  24 in total

1.  Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.

Authors:  J E Park; J Y Kim; H S Kim; W H Shim
Journal:  AJNR Am J Neuroradiol       Date:  2020-10-15       Impact factor: 3.825

2.  Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas.

Authors:  G M Conte; L Altabella; A Castellano; V Cuccarini; A Bizzi; M Grimaldi; A Costa; M Caulo; A Falini; N Anzalone
Journal:  Eur Radiol       Date:  2019-04-10       Impact factor: 5.315

3.  Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Authors:  Zongfang Li; Wei Zhao; Bo He; Tong San Koh; Yanxi Li; Yizhen Zeng; Zhuo Zhang; Jingzhong Zhang; Zujun Hou
Journal:  Contrast Media Mol Imaging       Date:  2020-11-22       Impact factor: 3.161

Review 4.  Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Authors:  Jill M Abrigo; Daniel M Fountain; James M Provenzale; Eric K Law; Joey Sw Kwong; Michael G Hart; Wilson Wai San Tam
Journal:  Cochrane Database Syst Rev       Date:  2018-01-22

5.  Dynamic susceptibility MR perfusion imaging of the brain: not a question of contrast agent molarity.

Authors:  Valentina Panara; Piero Chiacchiaretta; Matteo Rapino; Valerio Maruotti; Matteo Parenti; Eleonora Piccirilli; Andrea Delli Pizzi; Massimo Caulo
Journal:  Neuroradiology       Date:  2021-09-23       Impact factor: 2.804

6.  Assessment of quantitative dynamic contrast-enhanced MRI in distinguishing different histologic grades of breast phyllode tumor.

Authors:  Zhilong Yi; Mingwei Xie; Guangzi Shi; Ziliang Cheng; Hong Zeng; Ningyi Jiang; Zhuo Wu
Journal:  Eur Radiol       Date:  2021-09-07       Impact factor: 7.034

7.  Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.

Authors:  M D Lee; G L Baird; L C Bell; C C Quarles; J L Boxerman
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

8.  Static 18F-FET PET and DSC-PWI based on hybrid PET/MR for the prediction of gliomas defined by IDH and 1p/19q status.

Authors:  Shuangshuang Song; Leiming Wang; Hongwei Yang; Yongzhi Shan; Ye Cheng; Lixin Xu; Chengyan Dong; Guoguang Zhao; Jie Lu
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 5.315

9.  Specific Preoperative Dynamic Contrast-Enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of Glioblastoma Tissue and Predict Recurrence.

Authors:  Mohammed A Azab; Sherief Ghozy; Sherif F Hassanein; Ahmed Y Azzam
Journal:  Cureus       Date:  2021-06-08

10.  Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).

Authors:  Ramon F Barajas; Letterio S Politi; Nicoletta Anzalone; Heiko Schöder; Christopher P Fox; Jerrold L Boxerman; Timothy J Kaufmann; C Chad Quarles; Benjamin M Ellingson; Dorothee Auer; Ovidiu C Andronesi; Andres J M Ferreri; Maciej M Mrugala; Christian Grommes; Edward A Neuwelt; Prakash Ambady; James L Rubenstein; Gerald Illerhaus; Motoo Nagane; Tracy T Batchelor; Leland S Hu
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.